Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Read more about Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting Read more about Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting Read more about Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting Read more about Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting Iovance Biotherapeutics to Present at Upcoming Conferences Read more about Iovance Biotherapeutics to Present at Upcoming Conferences Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates Read more about Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021 Read more about Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021 Iovance Biotherapeutics to Host Conference Call and Webcast to Highlight Data at Society for Immunotherapy of Cancer (SITC) Annual Meeting Read more about Iovance Biotherapeutics to Host Conference Call and Webcast to Highlight Data at Society for Immunotherapy of Cancer (SITC) Annual Meeting Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapies Across Multiple Solid Tumors and Treatment Settings at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting Read more about Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapies Across Multiple Solid Tumors and Treatment Settings at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) in the Philadelphia Navy Yard Read more about Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) in the Philadelphia Navy Yard Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Read more about Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting Read more about Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting Read more about Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting Read more about Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Iovance Biotherapeutics to Present at Upcoming Conferences Read more about Iovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates Read more about Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021 Read more about Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021
Iovance Biotherapeutics to Host Conference Call and Webcast to Highlight Data at Society for Immunotherapy of Cancer (SITC) Annual Meeting Read more about Iovance Biotherapeutics to Host Conference Call and Webcast to Highlight Data at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapies Across Multiple Solid Tumors and Treatment Settings at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting Read more about Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapies Across Multiple Solid Tumors and Treatment Settings at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) in the Philadelphia Navy Yard Read more about Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) in the Philadelphia Navy Yard
